Welcome to our dedicated page for AKTIS ONCOLOGY news (Ticker: AKTS), a resource for investors and traders seeking the latest updates and insights on AKTIS ONCOLOGY stock.
Aktis Oncology, Inc. (Nasdaq: AKTS) is a clinical-stage oncology company focused on targeted radiopharmaceuticals for solid tumors, and its news flow reflects this specialization. Company announcements emphasize progress in its miniprotein radioconjugate platform, which is designed to deliver radioisotopes selectively to tumors while limiting exposure to normal tissues.
News related to Aktis Oncology includes capital markets milestones, such as the closing of its upsized initial public offering and the start of trading on the Nasdaq Global Select Market under the AKTS ticker. These updates provide context on how the company is financing its research and development activities in targeted alpha radiopharmaceuticals.
Investors and observers can also expect coverage of pipeline developments. Aktis Oncology has highlighted programs such as AKY-1189 and AKY-2519, as well as its most advanced program targeting Nectin-4 with a miniprotein radioconjugate that it describes as having multi-indication potential across multiple tumor types. News may discuss clinical progress, platform refinements, and efforts to expand the reach of its radiopharmaceutical candidates to larger patient populations.
Another recurring theme in Aktis Oncology news is its strategic collaboration with Eli Lilly and Company, which is intended to apply the company’s miniprotein platform to novel radioconjugates outside its proprietary pipeline. Updates may reference how this collaboration fits into the company’s broader strategy.
For readers following AKTS, the news page offers a way to track developments in its clinical programs, financing events, and partnership activities over time. Regularly reviewing this coverage can help provide a clearer picture of how the company’s radiopharmaceutical platform and solid tumor pipeline are evolving.
Akoustis, Inc. (NASDAQ: AKTS) will hold an investor update call on November 2, 2020, at 8:00 a.m. ET to discuss its business outlook and recent developments. The call is open for questions and will be accessible via telephone or webcast. Akoustis, a leader in bulk acoustic wave (BAW) RF filters, has entered production in multiple sectors, including 5G and high-band WiFi, adding 15 new filters to its catalog this year. The company focuses on innovation in RF technology targeting high-performance applications.
Akoustis Technologies, Inc. (AKTS) announced the shipment of its fourth XBAW™ filter solution targeting 5G small cell networks in Asia, set for commercial production in early 2021. The new filter operates in the n79 band, following previous wins in n77 and n79 with a tier-1 customer. The CEO highlighted a strategy to expand their customer base among tier-1 and tier-2 OEMs. The small cell 5G market, expected to grow from $381 million in 2018 to $3.5 billion by 2025, is driving demand for Akoustis' advanced RF filter technology.
Akoustis Technologies (AKTS) announced a design win and pre-production order for its band n79 XBAW™ filters from a new 5G small cell customer. This marks the second engagement in the 5G small cell infrastructure sector, with Akoustis having over five active engagements. The new customer aims to finalize qualifications for its 5G network equipment by early 2021. Akoustis has also begun shipping two RF filter designs for its first 5G client. The small cell 5G market is projected to grow significantly, from $381 million in 2018 to approximately $3.5 billion by 2025, reflecting a CAGR of 37%.
Akoustis Technologies (NASDAQ: AKTS) announced its participation in the 4th Annual Lake Street Best Ideas (Big4) Growth Conference on September 17, 2020. Senior management will hold virtual meetings due to social distancing measures amid the Covid-19 pandemic. Akoustis is set to start production in multiple markets, such as 5G network infrastructure and high-band WiFi, boasting 14 new filters in its catalog, including various WiFi and 5G filters. The company targets multi-billion-dollar RF filter markets with its advanced XBAW manufacturing process.
Akoustis Technologies (NASDAQ: AKTS) announced its participation in the IEEE International Ultrasonics Symposium, showcasing advancements in their XBAW™ technology. The symposium runs virtually from September 6-11, 2020, with Akoustis presenting two key lectures on high-power 3.5 GHz filters and novel piezoelectric materials for 5G applications. CEO Jeff Shealy emphasized the high-performance capabilities of their products, which support various markets, including 5G network infrastructure. The company has expanded its product catalog with 14 new RF filters, enhancing its position in the growing RF filter market.
Akoustis Technologies has secured a significant third design win for its 5G small cell network infrastructure filters from a tier-1 customer, with production anticipated in the second half of 2020. The XBAW filters are designed for 5G band n79 and complement earlier design wins. Akoustis is engaged with multiple other OEMs to expand its offerings in the market, which is projected to grow significantly. The company's product catalog now includes 14 filters, targeting high demand for advanced RF solutions across various applications.
Akoustis Technologies has launched the industry's first and only tandem ultra-wideband BAW-based filter solution tailored for WiFi 6E, covering the 5.1 to 7.1 GHz spectrum. The company received its first order from a tier-1 enterprise customer for 5.5 GHz and 6.5 GHz filters, aimed at supporting next-generation MU-MIMO platforms, with production expected to ramp in H1 2021. Akoustis anticipates this new filter solution to drive significant revenue growth, leveraging its unique position in the emerging WiFi 6E market.
Akoustis Technologies, Inc. (AKTS) hosted an investor call on August 24, 2020, to discuss its business outlook. The company reported a net revenue of $365,000 for Q4 FY20, a 350% increase in core filter product revenue, but incurred a GAAP operating loss of $8.2 million. Despite challenges due to COVID-19, Akoustis announced key design wins in 5G small cell infrastructure and advanced WiFi technologies. The firm ended Q4 with cash reserves of $44.4 million, up from $39.7 million in Q3, amid expanding product lines and strategic collaborations with tier-1 OEMs.
Akoustis Technologies (NASDAQ: AKTS) announced its participation in the 23rd Annual Oppenheimer Technology, Internet & Communications Conference, scheduled to occur virtually on August 11-12, 2020. The event is adapted for social distancing amid the Covid-19 pandemic. Akoustis is gearing up to produce high-frequency XBAW filters for various markets, including 5G networks and advanced WiFi technologies. The company has expanded its offerings with 14 new filters, targeting mobile devices and defense applications. Interested investors can schedule meetings via Oppenheimer or Akoustis' investor relations.
Akoustis Technologies (NASDAQ: AKTS) will showcase its XBAW technology and BAW filter solutions at the IEEE MTT-S International Microwave Symposium (IMS2020) from August 4-6, 2020. The virtual booth will cater to different regions with live hours focused on Europe, USA, and Asia. Akoustis will present applications for 5G infrastructure, WiFi 6, and defense. The company has expanded its product catalog with 14 new filters and is set to enter production in multiple markets. Interested parties can register for meetings via the IMS2020 registration link.